NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

A new drug, MED6-189, targets both the apicoplast and vesicular trafficking pathways in drug-sensitive and resistant strains of _Plasmodium falciparum_, preventing resistance development and showing efficacy in humanized mouse models and against other zoonotic Plasmodium parasites.

Roth/MKM maintains Buy rating on TFF Pharmaceuticals (NASDAQ:TFFP) with $30.00 price target, following TFFP's preclinical results showcasing Thin Film Freezing (TFF) technology's superiority in inhalation drug delivery. TFFP's TFF technology outperformed traditional methods, demonstrating better drug deposition and distribution in a rat model, potentially enhancing treatment efficacy and reducing toxicity. The company's advancements in drug delivery and recent partnerships with Emory University and Cleveland Clinic, funded by a $2.97 million grant, highlight its innovation potential. However, TFFP faces financial challenges, including rapid cash burn, negative gross profit margin, and a significant stock decline, with no TFF-based drug yet approved by the FDA.

The NIH's RECOVER initiative shifts focus to clinical trials for long COVID under RECOVER-TLC, addressing previous criticism for lack of pharmaceutical intervention studies. The initiative aims to expedite responses to treatment submissions and establish standardized trial endpoints, crucial for attracting industry investment and FDA approval.

PfSPZ vaccine trials in Mali showed safety and efficacy in adults and women anticipating pregnancy, with significant protection against malaria parasitemia and clinical malaria.

EC approves Bavarian Nordic’s Imvanex for adolescents aged 12 to 17, based on CHMP recommendation and NIH-sponsored study showing non-inferior immune responses and safety profile.

Tami McGraw, severely allergic to red meat, found relief through Xolair, originally for asthma, which also reduced her food allergies. After years of off-label use, Xolair was approved for food allergies in 2023, offering protection against accidental exposure and transforming lives, though it's not a cure. The drug's approval followed a pivotal clinical trial, OUtMATCH, which showed significant improvement in patients allergic to multiple foods. Xolair's potential to treat multiple allergies simultaneously and enhance oral immunotherapy effectiveness is under study.

Researchers analyzed vaginal swabs from VOICE study participants to identify 14 BV-associated bacterial taxa and 6 inflammatory proteins linked to increased HIV risk. High concentrations of these markers, particularly IP-10, distinguished women at highest risk. The study also found that Lactobacillus crispatus was associated with protection against HIV. Future prevention efforts could involve testing for high-risk bacteria and exploring antibiotic or probiotic treatments.

Crestone announces positive Phase 2 trial results for CRS3123 in treating C. difficile infections, showing high clinical cure rates, low recurrence, and safety. NIAID funds $4.5 million for further studies.

Crestone announces positive Phase 2 results for CRS3123 in treating C. difficile infections (CDI), showing high clinical cure rates and lower recurrence compared to vancomycin. CRS3123, a novel drug, maintains gut microbiota, addressing urgent need for effective CDI therapy.

Food allergies, affecting 8% of children and 6.2% of adults, can cause severe reactions requiring emergency care. Early allergen exposure may reduce future allergy risks. Advances include oral immunotherapies and FDA-approved drugs like Xolair, aiming to retrain the immune system. Genetics and environmental factors contribute to rising allergies, with research exploring prevention and treatment.